Wei Wang

Wei Wang has extensive work experience in the field of biological research and development. Starting from 2022, Wei Wang has been working as the Senior Director of Research at T-Therapeutics Ltd. Prior to that, from 2015 to 2019, they served as the Group Leader for Bispecific antibody development at Kymab Ltd. Before joining Kymab Ltd, Wei Wang worked at the Wellcome Trust Sanger Institute from 2005 to 2015, first as a Postdoctoral Fellow and then as a Staff Scientist.

Wei Wang began their education at Fudan University, where they earned a Bachelor of Science degree in Microbiology from 1994 to 1998. They then pursued a Master of Science degree in Genetics at the same institution from 1998 to 2001. Afterward, Wei Wang attended the University of Cambridge, obtaining a Doctor of Philosophy (PhD) degree in Mouse Genetics from 2001 to 2005.